News

Personalized Medicine Coalition notes uptick in diagnostic-influenced drug approvals

Pharmacies sue PBMs for restraint of trade, while payers question their activities

Deal value soared above $300 billion in 2015, but will the dealmaking sustain Big Pharma companies?

Industry is doing better at filing studies, but the agency is falling behind reviews, says GAO

A 'moon shot' to cure cancer is part of Obama's last Address

Controlled environment protects cold chain shipments in transit

Construction index shows a steady level of North American activity

ZIMonitor tracking service provides remote monitoring

'Innovation' is the recurring theme

Combination expands breadth of commercialization and compliance services

List includes 21 new orphan drugs, and of the 45, 15 are cold chain products

Innomar unit acquires Cameron Stewart LifeScience (CSL), provider of copay cards

Fast-growing pharma services provider will expand its global presence

Company partners with Teikoku for the latter's first marketed oncology product, and earns a milestone payment from Teva

Pharmacists (No. 2) and medical doctors (No. 3) round out top rankings

TGaS Advisors' study predicts more sales ops budgeting--but more operational challenges

Beleaguered pharma company retreats from specialty distribution

Specialty distributors handled 33% of specialty pharmaceutical distribution in 2014

Hylis Pharmacy Solutions offers a window into PBM program costs

Expanding capacities and a wider range of geographies aid life sciences developers

LifeTrack app puts shipment status in the palm of your hand

Pharma companies are looking to the data service as a potential competitive advantage

Expansion of cloud-based services includes Amazon Web Services

Company's Chartered Network is relied on for annual shipments to Africa

No immediate legislative action arises from 18-month study

Merger of New Jersey's CGS with Rondo-Pak Inc. is planned

New Internet-based delivery company wants to take the waiting time out of prescription pickups

Plans for splitting Pfizer itself are put on hold